Bio-Rad outlines 2026 margin expansion and 0.5%-1.5% revenue growth guidance amid operational improvements

Bio-Rad Laboratories has outlined its 2026 outlook, guiding to 0.5%–1.5% revenue growth and margin expansion, citing operational improvements. The guidance provides a forward view on Bio-Rad’s expected performance and execution priorities, which can influence investor expectations and competitive positioning within life science tools and diagnostics.